Insulet (PODD) Stock Forecast & Price Target

Insulet is supported by strong demand for Omnipod, with 2Q sales of $801.7M beating expectations as U.S. Omnipod revenue rose 20.1% to $544.1M and OUS growth accelerated 32.9% cc to $251.8M, while gross margin of 72.9% and operating margin of 19.3% also topped consensus. The company’s differentiated, smartphone-controlled disposable insulin delivery system has already been adopted by more than 600,000 insulin-dependent patients worldwide since FDA approval in 2005, reinforcing the scale and durability of its installed base. Although 2026 guidance was trimmed on softer U.S. retention and utilization trends in Type 2 patients, management still expects OUS growth of 30-32% and adj. EPS growth above 30%, highlighting a profitable growth model with meaningful pipeline and margin support.

Insulet is facing a deteriorating fundamental setup as lower U.S. Omnipod growth, weaker Type 2 retention and utilization, and mixed management messaging have increased uncertainty around the business’s near-term trajectory. Even after 2Q revenue of $801.7M, guidance was cut, with U.S. Omnipod growth trimmed to 17%-19% and Q3 sales expected at $826.0M-$840.0M, while drug delivery sales are set to decline about 20%, highlighting pressure outside the core franchise. With more than 98% of revenue tied to Omnipod, intensifying tubeless competition, recall-related credibility issues, and a likely 2027+ competitive inflection threaten multiple compression and make sustained recovery difficult to underwrite.